Open AccessDramatic resolution of disseminated pyoderma gangrenosum associated with monoclonal gammopathy after therapy with bortezomib and dexamethasone
Author(s) -
VelascoTamariz Virginia,
CarreñoTarragona Gonzalo,
TousRomero Fátima,
Gilde la Cruz Elena,
MartínClavero Estela,
RiveraDíaz Raquel
Publication year - 2017
Publication title -
international wound journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.867
H-Index - 63
eISSN - 1742-481X
pISSN - 1742-4801
DOI - 10.1111/iwj.12746
Subject(s) - medicine , pyoderma gangrenosum , bortezomib , multiple myeloma , dexamethasone , monoclonal gammopathy of undetermined significance , dermatology , monoclonal gammopathy , gammopathy , monoclonal , disease , immunology , monoclonal antibody , antibody
Pyoderma gangrenosum (PG) is an uncommon inflammatory and ulcerative skin disorder, which is commonly associated with systemic conditions such as inflammatory bowel disease, arthritis and haematological malignancies. It is widely stated that control of the underlying diseases may lead to resolution of PG. However, standard of care dictates that patients suffering with monoclonal gammopathy of undetermined significance or smouldering multiple myeloma (MM) should not receive therapy unless they progress to symptomatic MM. Here, we report a woman in her 40s with a disseminated corticodependent PG, resistant to any treatment attempted, including anti‐tumoral necrosis factor (TNF) therapy in which bortezomib–dexamethasone regimen results in dramatic healing of all lesions in only a month. This case supports the belief that treatment of the underlying monoclonal gammopathy could be necessary when PG presents as an aggressive, non‐responding skin disease.